TICLOPIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Ticlopidine Hydrochloride patents expire, and what generic alternatives are available?
Ticlopidine Hydrochloride is a drug marketed by Actavis Elizabeth, Apotex, Chartwell Rx, Mylan, Natco Pharma, Sun Pharm Inds Inc, Teva, and Watson Labs. and is included in nine NDAs.
The generic ingredient in TICLOPIDINE HYDROCHLORIDE is ticlopidine hydrochloride. There are nine drug master file entries for this compound. Additional details are available on the ticlopidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ticlopidine Hydrochloride
A generic version of TICLOPIDINE HYDROCHLORIDE was approved as ticlopidine hydrochloride by APOTEX on July 1st, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TICLOPIDINE HYDROCHLORIDE?
- What are the global sales for TICLOPIDINE HYDROCHLORIDE?
- What is Average Wholesale Price for TICLOPIDINE HYDROCHLORIDE?
Summary for TICLOPIDINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 113 |
Clinical Trials: | 39 |
Patent Applications: | 1,935 |
DailyMed Link: | TICLOPIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TICLOPIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ain Shams University | Phase 3 |
Kafrelsheikh University | Phase 3 |
Janssen Research & Development, LLC | Phase 1 |